Study #2022-0354
A Phase 1a/1b Study of ELVN-001 for the Treatment of Chronic Myeloid Leukemia
MD Anderson Study Status
Enrolling
Treatment Agent
ELVN-001
Description
The purpose of this study is to evaluate the safety, tolerability and determine the recommended dose for further clinical evaluation of ELVN-001 in patients with chronic myeloid leukemia with and without T315I mutations in patients who are relapsed, refractory or intolerant to TKIs.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Cml
Study phase:
Phase I
Physician name:
Koji Sasaki
Department:
Leukemia
For general questions about clinical trials:
1-855-319-9556
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.